Trends in Buprenorphine Prescribing Among Adults with Opioid Use Disorder and Coexisting HIV or Viral Hepatitis, 2015–2025
We examined buprenorphine prescribing among adults in the United States with opioid use disorder or other opioid-related diagnoses and coexisting HIV, hepatitis B, or hepatitis C from 2015 to 2025. Using the TriNetX USA Minimal Date Shift Network, we constructed annual cohorts and assessed encounter-day buprenorphine prescribing, with and without chronic pain diagnoses. Prescribing rose from 6% in 2015 to 17% in 2020, then plateaued at 16-19% through 2025, with marked attenuation after 2020. Despite expanded prescriber eligibility, most were not prescribed buprenorphine at clinical contact, suggesting regulatory reform alone is insufficient and that integrated, systemic approaches are needed.
Authors
- Siran M. Koroukian (ORCID: https://orcid.org/0000-0002-8106-9581)
- Philip R. Wang (ORCID: https://orcid.org/0000-0003-2973-529X)
- Margaret A. Miller (ORCID: https://orcid.org/0000-0003-1620-9303)
- Corrilynn O. Hileman (ORCID: https://orcid.org/0000-0001-9849-0914)
- David C. Kaelber (ORCID: https://orcid.org/0000-0001-7855-9515)
- Akhil Anand (ORCID: https://orcid.org/0000-0003-4132-2690)
- Ashley Hailer
Institutions
- Brigham and Women's Hospital (US)
- MetroHealth (US)
- Cleveland Clinic (US)
- Harvard University (US)
- University Hospitals of Cleveland (US)
- University School (US)
- MetroHealth Medical Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- AIDS and Behavior
- Published
- 2026-08-25
- DOI
- https://doi.org/10.1007/s10461-026-05288-y
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Case Western Reserve University
- School of Medicine, Case Western Reserve University
- National Institutes of Health
- Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University
- National Center for Advancing Translational Sciences